Advertisement

Molecular and Cellular Biochemistry

, Volume 415, Issue 1–2, pp 29–38 | Cite as

Hypoxia inhibits mesenchymal stem cell proliferation through HIF1α-dependent regulation of P27

  • Sanjay KumarEmail author
  • Meenal Vaidya
Article

Abstract

Stem cells have inherent properties of self-renewal and differentiation. High percentage of transplanted stem cells (95 %) die into ischemic heart due to unfavorable environment where in hypoxia considered among major contributing factors. Hypoxia inducible factor-1 α is a well-known transcription factor which robustly induced during hypoxia and an essential factor for adaptation under lower oxygen tension. The effects of hypoxia onto stem cells and its cell cycle are poorly understood. Mesenchymal stem cells were isolated from adult male Fischer-344 rats bone marrow and kept under hypoxia (1 % O2). Cell survival and proliferation were studied using MTT and CFSE assay which showed reduced proliferation rate with an arrest in G0/G1 phase of cell cycle using flow cytometry. Western blot analysis revealed an increase in expressions of HIF-1α along with P53, a tumor suppressor gene. Cyclin-dependent kinase inhibitor (CDKI), p27 was significantly increased, in concordance with the findings, cyclin D1 was also reduced under hypoxia and forestalling S phase entry. In addition, loss of function study with HIF-1α knockdown revealed progression of cell cycle even under hypoxia. Knocking down p27 abrogated the hypoxia-induced G1 checkpoint, suggesting a key regulator of G1/S transition in hypoxic cells. Hypoxia could cause HIF-1α-dependent increase in the expression of p27 leading to cell cycle arrest in G0/G1 phase. The demonstration of the molecular mechanism of hypoxia-induced G1/S regulation provides insight into a fundamental response of stem cells to low oxygen tension.

Keywords

Mesenchymal stem cell Hypoxia HIF1α P27 G0/G1 arrest 

Notes

Acknowledgments

This work was supported by National Institutes of Health (NIH) Grants # RO1 HL-087246 (M.A). We thank professor Muhammad Ashraf, University of Illinois, Chicago for providing financial support to this work.

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276(5309):71–74CrossRefPubMedGoogle Scholar
  2. 2.
    Pittenger MF, Martin BJ (2004) Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95(1):9–20CrossRefPubMedGoogle Scholar
  3. 3.
    Kumar S, Ashraf M (2015) Tadalafil, a phosphodiesterase inhibitor protects stem cells over longer period against hypoxia/reoxygenation injury through STAT3/PKG-I signaling. Stem Cells Dev 24(11):1332–1341CrossRefPubMedGoogle Scholar
  4. 4.
    Schmaltz C, Hardenbergh P, Wells A, Fisher DA (1998) Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 18:2845–2854CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsujimoto Y (1995) Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature 374:811–813CrossRefPubMedGoogle Scholar
  6. 6.
    Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV (2001) Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 276:7919–7926CrossRefPubMedGoogle Scholar
  7. 7.
    Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8(5):588–594CrossRefPubMedGoogle Scholar
  8. 8.
    Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733–25741CrossRefPubMedGoogle Scholar
  9. 9.
    Maxwell PH, Wiesener M, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275CrossRefPubMedGoogle Scholar
  10. 10.
    Tanimoto K, Makino Y, Pereira T, Poellinger L (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19:4298–4309CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845CrossRefPubMedGoogle Scholar
  13. 13.
    Jiang B, Rue HE, Wang GL, Roe R, Semenza GL (1996) Dimerization, DNA binding and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271:17771–17778CrossRefPubMedGoogle Scholar
  14. 14.
    Wang GL, Semenza GL (1993) General involvement of hypoxiainducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90:4304–4308CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Iyer NV, Kotch KL, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL (1998) Cellular and developmental control of O2 homeostasis by hypoxiainducible factor 1 alpha. Genes Dev 12:149–162CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269:23757–23763PubMedGoogle Scholar
  17. 17.
    Plana-Silva MD, Weinberg RA (1997) The restriction point and control of cell proliferation. Curr Opin Cell Biol 9:768–772CrossRefGoogle Scholar
  18. 18.
    Green SL, Giaccia AJ (1998) Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer J Sci Am 4:218–223PubMedGoogle Scholar
  19. 19.
    Kumar S (2014) P53 induction accompanying G2/M arrest upon knockdown of tumor suppressor HIC1 in U87MG glioma cells. Mol Cell Biochem 395(1–2):281–290CrossRefPubMedGoogle Scholar
  20. 20.
    Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E, Keshet E (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485–490CrossRefPubMedGoogle Scholar
  21. 21.
    Ludlow JW, Howell R, Smith HC (1993) Hypoxic stress induces reversible hypophosphorylation of pRB and reduction in cyclin A abundance independent of cell cycle progression. Oncogene 8:331–339PubMedGoogle Scholar
  22. 22.
    Herrera RE, Sah VP, Williams BO, Makela TP, Weinberg RA, Jacks T (1996) Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol 16:2402–2407CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ryan HE, Lo J, Johnson RS (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17:3005–3015CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Green SL, Freiberg RA, Giaccia AJ (2001) p21 (Cip1) and p27 (Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol Cell Biol 21(4):1196–1206CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60:4010–4015PubMedGoogle Scholar
  26. 26.
    Seagroves TN, Ryan H, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS (2001) Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 21:3436–3444CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ Jr, Giaccia, AJ (1994) Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 14:6264–6272CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Alevizopoulos K, Catarin B, Vlach J, Amati B (1998) A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27(Kip1). EMBO J 17:5987–5997CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14:34–44PubMedPubMedCentralGoogle Scholar
  30. 30.
    Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cell 78: 59–66Google Scholar
  31. 31.
    Toyoshima H, Hunter T (1994) p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67–74CrossRefPubMedGoogle Scholar
  32. 32.
    Coats S, Flanagan WM, Nourse J, Roberts JM (1996) Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272:877–880CrossRefPubMedGoogle Scholar
  33. 33.
    Lloyd RV, Erickson L, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313–323CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Burnett School of Biomedical Sciences, College of MedicineUniversity of Central FloridaOrlandoUSA
  2. 2.Department of BiochemistryCentral University of HaryanaMahendergarhIndia
  3. 3.Department of BiochemistryM.G.M Medical CollegeIndoreIndia

Personalised recommendations